BioSpace News Archive

Nordic Nanovector ASA announces that the company and its collaborators will present data and analyses from its preclinical studies with Betalutin® and with 212Pb-NNV003, a next-generation targeted alpha therapy comprising Nordic Nanovector’s chimeric anti-CD37 antibody coupled with the alpha-particle-generator lead-212, at the Society of Nuclear Medicine & Molecular Imaging 2019 Annual Meeting, to be held in Anaheim, CA, USA on 22-24 June.

GT Healthcare Capital Partners has launched an AI-driven drug development company in Shanghai with $27 million financial backing today.

Regulus Therapeutics Inc. announced Jake Nunn and Simos Simeonidis, Ph.D. have been appointed to the Company’s board of directors.

Leading Behavioral Healthcare Centers Become First National Providers to Add FDA-approved Esketamine Nasal Spray to Treatment Options

TrialResults.com helps lead the way in assisting clinical trial sponsors to #BeTransparent

HP Healthcare Edition notebooks, All-in-One PCs and clinical review displays are compatible with Clorox Healthcare® Bleach Germicidal Wipes

Innovia Medical has partnered with Medical Device Resource Corporation.

RMAT designation follows positive Phase 2 proof-of-concept data published in the Journal of Clinical Oncology (JCO) for Viralym-M, an allogeneic, off-the-shelf multi-virus specific T-cell therapy

Longer-term results from IMMhance showed 73 percent and 72 percent of patients treated with continuous SKYRIZI™ (risankizumab) experienced complete skin clearance (defined as sPGA 0 and PASI 100, respectively) at week 94, among patients who achieved sPGA 0/1 at week 28

Leap Therapeutics, Inc. announced that Christopher K. Mirabelli, Ph.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the 2019 Raymond James Life Sciences and MedTech Conference, being held in New York City on June 18-19, 2019.